|
| |
GenentechConsidered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 30 years, using human genetic information to discover, develop, commercialize and manufacture biotherapeutics that address significant unmet medical needs. Today, Genentech is among the world's leading biotech companies, with multiple products on the market for serious or life-threatening medical conditions and over 50 projects in the pipeline. The company is the leading provider of anti-tumor therapeutics in the United States. With its strength in all areas of the drug development process — from research and development to manufacturing and commercialization — Genentech continues to transform innovative science into breakthrough therapies for patients. For more general information about the company, visit our corporate overview section.
| Contact Details: |
| 1 DNA Way |
| South San Francisco |
| CA |
| 94080 |
| United States of America |
| Tel: | 650 225 1000 |
| Fax: | 650 225 6000 |
| Email: | |
| WWW: | www.gene.com/
|
|
Loading...
|
Recent Publications by Genentech: |  |
Long-Term Safety of Recombinant Human Growth Hormone in Children.
Background: Between 1985 and 2006, the National Cooperative Growth Study... | 13th November, 2009
| Columbia University Medical Center (J.B.), New York, New York 10032;
| J Clin Endocrinol Metab. 2009 Nov 11.
DOI Direct Link |
ALK1 signaling regulates early postnatal lymphatic vessel development.
In vertebrates, endothelial cells form two hierarchical tubular networks,... | 12th November, 2009
| Department of Tumor Biology and Angiogenesis, Division of Research,
| Blood. 2009 Nov 10.
DOI Direct Link |
New genomic cancer test allows better decisions.
In vertebrates, endothelial cells form two hierarchical tubular networks,... | 12th November, 2009
| Valued-Based Health Department, Genentech Inc, USA.
| Manag Care. 2009 Oct;18(10):59-60.
|
Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer.
PURPOSE: Pertuzumab is a humanized monoclonal antibody that inhibits human... | 11th November, 2009
| Department of Gynecologic Oncology, Emory University, Atlanta, GA;
| J Clin Oncol. 2009 Nov 9.
DOI Direct Link |
Recent asthma exacerbations predict future exacerbations in children with severe or difficult-to-treat asthma.
BACKGROUND: Children with severe/difficult-to-treat asthma experience high... | 10th November, 2009
| Genentech, Inc, South San
| J Allergy Clin Immunol. 2009 Nov;124(5):921-7.
DOI Direct Link |
→View more Genentech research publications. |
Press Releases on Genentech:
|
 |
| Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013 |
20th November, 2009 |
Reportlinker |
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
|
| Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018 |
17th November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat
|
| ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours |
16th November, 2009 |
|
LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
|
| American Heart Association Late-breaking Clinical Trial Report: Risks of Anemia Drug Outweigh Benefits in Cardiovascular Disease Patients With Diabetes and Kidney Disease |
16th November, 2009 |
American Heart Association |
Study highlights:
- Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke.
- This first large,
|
| ACCU-CHEK(R) Launches Web Challenge to Bring a Little Fun to an Otherwise Serious Disease - Diabetes: the Born in the USA Meter Skin Design Challenge: Will Your Patriotic Skin Win? |
12th November, 2009 |
Roche Diabetes Care |
-- Hit SAVE
Enter your skin design before the deadline, which is February 28, 2010.
All site visitors have the opportunity to vote for their favorite designs. From the top 50 vote-getters,
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 581 individuals from Genentech using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 840 times since April 2007, the link to the organisation's website has been followed 130 times Recent Search Terms used to find this page: 13 november 2009 georgia l ofra | genentech USA new york | genentech south carolina | genentech south carolina | genentech publications | genentech publications | Early Stage Pharmaceutical Development genentech | Genentech EXACT clinical trial | genentech news november 2009 | genentech nov 2009 | . Search for more companies in South San Francisco Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Genentech |
